AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21501692 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 282 μg
Number of subjects: 36
Study 21501692 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 148 μg
Number of subjects: 36
Study 21501692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 21501692 — intervention group
Group type: EXPERIMENTAL
Intervention: CIC‐HFA 282 μg and 148 μg
Number of subjects: 36
Study 18440674 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid pTHr DNA vaccine
Number of subjects: 0
Study 18440674 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA) vaccine
Number of subjects: 0
Study 18440674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16550943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks
Number of subjects: 78
Study 16550943 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide after oral prednisone
Number of subjects: 78
Study 16550943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone and intranasal budesonide
Number of subjects: 78
Study 16550943 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 78
Study 12520564 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery stenting
Number of subjects: 5806
Study 10752812 — intervention group
Group type: EXPERIMENTAL
Intervention: Hygrobac‐Dar HME (n = 21)
Number of subjects: 61
Study 10752812 — intervention group
Group type: EXPERIMENTAL
Intervention: Humid‐Vent HME (n = 20)
Number of subjects: 61
Study 10752812 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear‐Thermal HME (n = 20)
Number of subjects: 61
Study 10752812 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 61
Study 8884011 — intervention group
Group type: EXPERIMENTAL
Intervention: Sil-K
Number of subjects: 26
Study 8884011 — intervention group
Group type: COMPARATOR
Intervention: Epiderm
Number of subjects: 26
Study 7519702 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 24
Study 7519702 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg
Number of subjects: 24
Study 7519702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2843316 — intervention group
Group type: COMPARATOR
Intervention: 1 mCi Gold-198
Number of subjects: 46
Study 2843316 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mCi Gold-198
Number of subjects: 46
Study 30782759 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counsellor-led intervention incorporating a custom-designed communication aid
Number of subjects: 0
Study 29355002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus clomiphene
Number of subjects: 0
Study 29355002 — intervention group
Group type: COMPARATOR
Intervention: Control acupuncture plus clomiphene
Number of subjects: 0
Study 29355002 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene alone
Number of subjects: 0
Study 24329126 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward-primed go/no-go task
Number of subjects: 216
Study 24329126 — intervention group
Group type: COMPARATOR
Intervention: No reward priming in go/no-go task
Number of subjects: 216
Study 22926890 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate stent removal (group A)
Number of subjects: 40
Study 22926890 — intervention group
Group type: COMPARATOR
Intervention: Leaving the stent in place (group B)
Number of subjects: 40
Study 20655282 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-out prism bar vergences
Number of subjects: 30
Study 20655282 — intervention group
Group type: EXPERIMENTAL
Intervention: Vergence facility (12 base-out/3 base-in binocular prism flippers for 1 minute)
Number of subjects: 30
Study 20655282 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 minutes viewing with 6 prism diopters of base-out prism
Number of subjects: 30
Study 20655282 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Thorington method for measuring near phoria
Number of subjects: 30
Study 18362295 — intervention group
Group type: EXPERIMENTAL
Intervention: GH therapy for 1 year
Number of subjects: 14
Study 18362295 — intervention group
Group type: COMPARATOR
Intervention: Baseline GHD adults
Number of subjects: 14
Study 16818280 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 or 1.3 mg/m2 administered intravenously twice weekly for 2 weeks of a 3-week cycle for up to 8 cycles plus oral dexamethasone 20 mg on the day of and after each bortezomib dose
Number of subjects: 256
Study 16818280 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 256
Study 14585874 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g human albumin
Number of subjects: 976
Study 14585874 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 976
Study 10714140 — intervention group
Group type: EXPERIMENTAL
Intervention: Inference learning task
Number of subjects: 0
Study 10714140 — intervention group
Group type: COMPARATOR
Intervention: Standard classification learning task
Number of subjects: 0
Study 10714140 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of stimuli during learning
Number of subjects: 0
Study 8772600 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological hyperinsulinemia (0.67 vs. 2.00 mU/kg.min)
Number of subjects: 27
Study 8772600 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher degrees of physiological hyperinsulinemia
Number of subjects: 27
Study 1425271 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose only (2 mg/kg.min)
Number of subjects: 18
Study 1425271 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose+xylitol (1 mg/kg.min each)
Number of subjects: 18
Study 1425271 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-containing electrolyte solution (0.83 mg/kg.min glucose)
Number of subjects: 18
Study 6420383 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (500 mg/3 days)
Number of subjects: 9
Study 6420383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 31340623 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐rhG‐CSF
Number of subjects: 60
Study 31340623 — intervention group
Group type: COMPARATOR
Intervention: rhG‐CSF
Number of subjects: 60
Study 29517675 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai (SM) injection
Number of subjects: 40
Study 29517675 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (G)
Number of subjects: 40
Study 26990509 — intervention group
Group type: EXPERIMENTAL
Intervention: Early precut sphincterotomy (Group A)
Number of subjects: 375
Study 26990509 — intervention group
Group type: COMPARATOR
Intervention: Repeated papillary cannulation attempts followed by late precut (Group B)
Number of subjects: 375
Study 26990509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 375
Study 24759827 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART (initiated 2 weeks after tuberculosis treatment onset)
Number of subjects: 661
Study 24759827 — intervention group
Group type: COMPARATOR
Intervention: Late ART (initiated 8 weeks after tuberculosis treatment onset)
Number of subjects: 661
Study 24759827 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality
Number of subjects: 661
Study 22531338 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of 40-day stored autologous leukoreduced packed erythrocytes
Number of subjects: 10
Study 22531338 — intervention group
Group type: COMPARATOR
Intervention: Transfusion of 3-day stored autologous leukoreduced packed erythrocytes
Number of subjects: 10
Study 21300002 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid hemorrhage treatment (coiling, clipping)
Number of subjects: 77
Study 21300002 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 77
Study 21300002 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of SAH patients (coiled, clipped, perimesencephalic hemorrhage)
Number of subjects: 77
Study 17659645 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 9
Study 17659645 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study 16136270 — intervention group
Group type: EXPERIMENTAL
Intervention: DAART (early home-based physiotherapy intervention)
Number of subjects: 275
Study 16136270 — intervention group
Group type: EXPERIMENTAL
Intervention: STRETCH (group-based exercise and psychosocial intervention)
Number of subjects: 275
Study 16136270 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group
Number of subjects: 275
Study 11856927 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral position casting
Number of subjects: 99
Study 11856927 — intervention group
Group type: EXPERIMENTAL
Intervention: Pronated position casting
Number of subjects: 99
Study 11856927 — intervention group
Group type: EXPERIMENTAL
Intervention: Supinated position casting
Number of subjects: 99
Study 11856927 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all positions)
Number of subjects: 99
Study 10100390 — intervention group
Group type: EXPERIMENTAL
Intervention: Word frequency, repetition, and lexicality effects in word recognition tasks
Number of subjects: 0
Study 7790471 — intervention group
Group type: EXPERIMENTAL
Intervention: FAN bottles
Number of subjects: 6847
Study 7790471 — intervention group
Group type: COMPARATOR
Intervention: Standard aerobic BacT/Alert bottles
Number of subjects: 6847
Study 7790471 — intervention group
Group type: EXPERIMENTAL
Intervention: FAN bottles (subset of patients on antimicrobial therapy)
Number of subjects: 6847
Study 2359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Intervention (MI)
Number of subjects: 114
Study 2359309 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 114
Study 2359309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MI and Control)
Number of subjects: 114
Study 7390390 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidon
Number of subjects: 0
Study 7390390 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 0
Study 7390390 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromoprid
Number of subjects: 0
Study 7390390 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study 30122341 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin
Number of subjects: 173
Study 30122341 — intervention group
Group type: COMPARATOR
Intervention: 10 mg atorvastatin
Number of subjects: 173
Study 28248974 — intervention group
Group type: EXPERIMENTAL
Intervention: Green environment exposure (Collserola Natural Park)
Number of subjects: 26
Study 28248974 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue environment exposure (Castelldefels beach)
Number of subjects: 26
Study 28248974 — intervention group
Group type: COMPARATOR
Intervention: Urban environment exposure (Eixample neighbourhood)
Number of subjects: 26
Study 25946708 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard chemotherapy
Number of subjects: 0
Study 25946708 — intervention group
Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GMTZ)
Number of subjects: 0
Study 25946708 — intervention group
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Number of subjects: 0
Study 25946708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification II (cytarabine/mitoxantrone)
Number of subjects: 0
Study 25946708 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction I (cytarabine/daunorubicin/etoposide)
Number of subjects: 0
Study 25946708 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher AML risk group
Number of subjects: 0
Study 25946708 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 0
Study 24111288 — intervention group
Group type: EXPERIMENTAL
Intervention: Head care robot
Number of subjects: 54
Study 24111288 — intervention group
Group type: COMPARATOR
Intervention: Human nurse head care
Number of subjects: 54
Study 21327725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg (R group)
Number of subjects: 90
Study 21327725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus fenofibrate 200 mg (RF group)
Number of subjects: 90
Study 21327725 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus n-3 fatty acids 2 g (RN group)
Number of subjects: 90
Study 19235193 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 84
Study 19235193 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 84
Study 16614537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 1,200 mg/d
Number of subjects: 60
Study 16614537 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 15 mg/d
Number of subjects: 60
Study 16614537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15610312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional steroid injection (8 mg triamcinolone acetate into each quadrant)
Number of subjects: 21
Study 15610312 — intervention group
Group type: COMPARATOR
Intervention: Control group (SGBD only)
Number of subjects: 21
Study 15610312 — intervention group
Group type: EXPERIMENTAL
Intervention: Total periodic dilatation index in study group
Number of subjects: 21
Study 15610312 — intervention group
Group type: COMPARATOR
Intervention: Total periodic dilatation index in control group
Number of subjects: 21
Study 11730397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet plus resistance training (n = 14)
Number of subjects: 26
Study 11730397 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet alone (n = 12)
Number of subjects: 26
Study 9164424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50-150 mg/day, mean 102 +/- 44 mg/day)
Number of subjects: 60
Study 9164424 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine (20-50 mg/day, mean 36 +/- 13 mg/day)
Number of subjects: 60
Study 9164424 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 60
Study 9164424 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 60
Study 9164424 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine vs Paroxetine
Number of subjects: 60
Study 7969676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysts of proximal origin (38 cysts)
Number of subjects: 50
Study 7969676 — intervention group
Group type: COMPARATOR
Intervention: Cysts of undetermined origin (12 cysts)
Number of subjects: 50
Study 7969676 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with proximal cysts
Number of subjects: 50
Study 7969676 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 50
Study 2884494 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid-phase radioimmunoassay for antibodies against neutrophil cytoplasm
Number of subjects: 0
Study 29370818 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week group-based moderate-intensity stepping exercise
Number of subjects: 224
Study 29370818 — intervention group
Group type: COMPARATOR
Intervention: 16-week health education
Number of subjects: 224
Study 27799299 — intervention group
Group type: EXPERIMENTAL
Intervention: Biobran (1 g/day), n = 16
Number of subjects: 37
Study 27799299 — intervention group
Group type: COMPARATOR
Intervention: PEG IFN plus ribavirin, n = 21
Number of subjects: 37
Study 24710641 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide-MR
Number of subjects: 57
Study 24710641 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 57
Study 24710641 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 57
Study 22099384 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydextrose (PDX; 8 g/d)
Number of subjects: 0
Study 22099384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20334680 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 213
Study 20334680 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 213
Study 20334680 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 213
Study 20334680 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 213
Study 19035875 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg allopurinol for 8 weeks
Number of subjects: 30
Study 19035875 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 30
Study 16555069 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme (nanofiller resin composite)
Number of subjects: 50
Study 16555069 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram (fine hybrid resin composite)
Number of subjects: 50
Study 16555069 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme
Number of subjects: 50
Study 16555069 — intervention group
Group type: COMPARATOR
Intervention: Tetric Ceram
Number of subjects: 50
Study 14634760 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation program + home-based computer-assisted training (114+/‐18 sessions over 12 months)
Number of subjects: 32
Study 14634760 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study 11565955 — intervention group
Group type: EXPERIMENTAL
Intervention: Loxoribine (doses: 1 mg/kg, 5 mg/kg, 10 mg/kg)
Number of subjects: 24
Study 11565955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 9183263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthoses (AFOs)
Number of subjects: 12
Study 9183263 — intervention group
Group type: COMPARATOR
Intervention: No ankle-foot orthoses (AFOs)
Number of subjects: 12
Study 8246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal glucose levels (<= 120 mg/dl)
Number of subjects: 616
Study 8246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia (> 120 mg/dl)
Number of subjects: 616
Study 8246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal mean glucose levels (<= 120 mg/dl) between Days 3 and 7
Number of subjects: 616
Study 8246057 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated mean glucose levels (> 120 mg/dl) between Days 3 and 7
Number of subjects: 616
Study 2937659 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone supplementation (P) given 12 to 15 hours and 1 hour before and 24 hours after laparoscopy (group B)
Number of subjects: 42
Study 2937659 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotropin given 12 hours before laparoscopy (group C)
Number of subjects: 42
Study 2937659 — intervention group
Group type: COMPARATOR
Intervention: No treatment in addition to normal IVF procedures (group A)
Number of subjects: 42
Study 29464879 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 120
Study 27467125 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence calculated as AUC (area under the curve) using a digital audio device attached to a dry powder inhaler over a 3-month period.
Number of subjects: 239
Study 24862240 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance Facilitating Intervention (AFI)
Number of subjects: 141
Study 24862240 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control group (CG)
Number of subjects: 141
Study 22865548 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagal nerve stimulation (VNS) for continuous intraoperative neuromonitoring (CIONM)
Number of subjects: 40
Study 22865548 — intervention group
Group type: COMPARATOR
Intervention: Routine intraoperative neuromonitoring (IONM)
Number of subjects: 40
Study 20479335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 6
Study 20479335 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN (10 mg)
Number of subjects: 6
Study 20479335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of sildenafil (50 mg) and ISMN (10 mg)
Number of subjects: 6
Study 20479335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 18493713 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (started at 250 mg qhs, increased to 1,500 mg bid as tolerated)
Number of subjects: 7
Study 18493713 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (treatment phase lasted 4 months)
Number of subjects: 7
Study 18493713 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (treatment for PMDD)
Number of subjects: 7
Study 15780443 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV) given once or twice
Number of subjects: 83
Study 15780443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 83
Study 12084594 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (100 J)
Number of subjects: 203
Study 12084594 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (150 J)
Number of subjects: 203
Study 12084594 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (200 J)
Number of subjects: 203
Study 12084594 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform (maximum 200 J)
Number of subjects: 203
Study 12084594 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic shock waveform
Number of subjects: 203
Study 10627637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified stem cell transplant regimen (HDCT with escalated melphalan 160 mg/m2, fractionated total body irradiation 12 Gy, and infusional etoposide 60 mg/kg)
Number of subjects: 100
Study 7549821 — intervention group
Group type: EXPERIMENTAL
Intervention: Real time ultrasound
Number of subjects: 102
Study 7549821 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 102
Study 1851649 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UH) 5000 units b.d.
Number of subjects: 1290
Study 1851649 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin 2500 units daily
Number of subjects: 1290
Study 1851649 — intervention group
Group type: EXPERIMENTAL
Intervention: Logiparin 3500 units daily
Number of subjects: 1290
Study 6815282 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg weekly for six weeks
Number of subjects: 20
Study 6815282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20